Soluble markers for the detection of hypoxia under antiangiogenic treatment

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 1159-1161

  Drevs, Joachim ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; Antiangiogenic treatment; Soluble marker

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; SELECTIN; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOXIA; MULTIPLE MYELOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; CELL HYPOXIA; HUMANS; NEOPLASMS;

EID: 0037561644     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Folkma J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416, 1972.
2. Sim BK, MacDonald NJ and Gubish ER: Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev 19: 181-190, 2000.
3. Drevs J, Droll A, Mrossj K and Unger C: Angiogenesis inhibition: Drugs in clinical trials. Onkologie 22: 282-290, 1999.
4. Libutti SK., Choyke P, Carrasquillo JA, Bacharach S and Neumann, RD: Monitoring responses to antiangiogenic agents using noninvasive imaging tests. Cancer J Sci Am 5: 252-256, 1999.
5. Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM and Mayr N: MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10: 903-907, 1999.
6. Mayr NA, Hawighorst H, Yuh WT, Essig M, Magnotta VA and Knopp MV: MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome. J Magn Reson Imaging 10: 267-276, 1999.
7. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N and Marme D: Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 7: 1992-1997, 2001.
8. Drevs J, Mross K, Reusch P, Peng B, Ball H, Henry A, Laurent D, Dugan M, Marine D and Unger C: Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK). Eur J Cancer 35: 283, 1999.
9. Thomas AL, Morgan B, Drevs J, Jivan A, Bilchert M, Horsfield M, Hennig J, Mross K, Henry A, Ball H, Peng B, Fuxius S, Unger C, O'Byrne K, Laurent D, Dugan M and Steward WP: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase I studies of the VEGF inhibitor PTK787/ZK222 584 in patients with liver metastases from colorectal cancer. Proc ASCO 20: a279, 2001.
10. Drevs J, Mross K, Fuxius S, MUller M, Putz B, Laurent D, Dugan M, Peng B, Chong J, Henry A, Marmd D and Unger C: A phase I dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastases of advanced cancer. Proc ASCO 20: a398, 2001.
11. Drevs J, Goldschmidt H, Neben K, Kasper. B, Hawighorst H, van Kaick G, Benner A, Reusch, P, Ho AD, Marmd D and Moehler TM: Soluble, endothelial specific, tyrosine kinase receptors (sFLT- I and sTIE-2) are correlating with disease activity markers and functional magnetic resonance imaging parameters in patients with multiple myeloma. Clinical Cancer Res a562, 2001.
12. Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C and Marmé D: PTK787/ZK222 584, a specific inhibitor of the VEGF receptor tyrosine kinases, primarily reduces tumor microvessels and induces changes in dynamic MRI measurements in murine renal cell carcinoma. Proc AACR 42: a5053, 2001.